EICHOR
● Not Yet Recruiting
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
Condition: Obesity · Metabolic Syndrome · Brown Adipose Tissue · Sponsor: Hallym University
About this study
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET/CT imaging before and after 24 weeks of treatment. Prior to each PET/CT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.
This description comes directly from the study's public registry record.
Talk to the study team
Hun Jee Choe Hallym University Dongtan Sacred Heart Hospital, MD, PhD · +82-31-8086-2869 · hunjeechoe@gmail.com
Hye Jeong Lee Hallym University Dongtan Sacred Heart Hospital, CRC · +82-10-4694-3886 · geumzzogi@naver.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Hallym University Dongtan Sacred Heart Hospital | Hwaseong-si, Gyeonggi-do, South Korea | — |
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07621640